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1. ABSTRACT 
 
 Candida albicans is the most frequent etiologic agent that causes opportunistic fungal infections called candidiasis, a 
disease whose systemic manifestation could prove fatal and whose incidence is increasing as a result of an expanding 
immunocompromised population. Here we review the role of interferon-gamma (IFN-γ) in host protection against invasive 
candidiasis. This cytokine plays an essential role in both the innate and adaptive arms of the immune response to candidiasis. We 
focus on recent progress on host-pathogen interactions leading to the production of IFN-γ by host cells. IFN-γ is produced by 
CD4 Th1, CD8, γδ T, and natural killer (NK) cells, essentially in response to both IL-12 and/or IL-18; more recently, a subset of 
C. albicans-specific Th17 cells have been described to produce both IL-17 and IFN-γ. IFN-γ plays an important role in the 
regulation of the immune system as well as in the control of the infectious process, as it is required for optimal activation of 
phagocytes, collaborates in the generation of protective antibody response, and favors the development of a Th1 protective 
response.  
 
2. INTRODUCTION 
 
Candida species are the most frequent cause of mucosal and invasive fungal infections (1-3). The leading cause of 
candidiasis, Candida albicans, resides as a commensal of the human mucosae and the gastrointestinal tract. In 
immunocompromised hosts, saprophytic colonization often leads to opportunistic mucosal or life-threatening deep organ 
infection. A wide range of factors that lead to various degrees of immunosuppression predispose patients to infections by 
Candida. These factors include a severe underlying disease (i.e. AIDS or leukaemia), impaired phagocytic function (i.e. 
neutropenia), and exogenous factors (such as wide spectrum antibiotic treatment, i.v. drug use, transplantation medicine, trauma, 
abdominal surgery). Haematogenous candidiasis is a frequent complication in the treatment of patients with acute leukaemia; 
oropharyngeal candidiasis, a common mucosal infection, occurs in the majority of AIDS patients, and vaginal candidiasis has 
been estimated to occur in approximately 75% of women at least once. Morbidity and mortality rates associated with 
haematogenous disseminated or invasive candidiasis remain unacceptably high, mainly due to the lack of an early and accurate 
diagnostic procedure, the limited arsenal of antifungal drugs and the emergence of resistant strains (3-6). 
     
Resistance to candidiasis requires the coordinated action of innate and adaptive immune defenses. The phagocytes, 
neutrophils and macrophages, can clear the pathogen, and furthermore macrophage activation leads to the release of several key 
mediators such as proinflammatory cytokines, which are important for protecting the host against disseminated candidasis (6). 
The specific detection of microbes by macrophages and dendritic cells is mediated by pattern recognition receptors (PRRs), 
germline-encoded, nonclonal receptors, that recognize microbial structures referred to as microorganism-associated molecular 
patterns (MAMPs). Phagocytic cells recognize C. albicans by a variety of PRRs including receptors for mannosyl/fucosyl 
glycoconjugates (CR3, MR, DC-SIGN, galectin-3, dectin-2), receptor for β-glucan (dectin-1), and Toll-like receptors (TLRs) (7-
11). TLRs are essential PRRs and constitute a family of receptors that mediate recognition of microbial challenges, subsequent 
inflammatory response and are also regulators of the adaptive responses (12, 13).  
 
It is accepted that antifungal CD4+ T helper 1 (Th1)-mediated responses play a central role in anti-C. albicans 
defenses, providing control of fungal infectivity through production of IFN-γ, which is required for optimal activation of 
phagocytes and for helping in the generation of protective antibody response (6). Interestingly, although protective immunity to 
C. albicans is mediated by Th1 cells, some Th2 cytokines, such as IL-4 and IL-10, are required for the maintenance of the anti-
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fungal immune protection (6, 14, 15); in addition, regulatory T cells (Treg), activated by IL-10 producing dendritic cells, are 
involved in the induction of memory protective immunity by negative regulation of antifungal Th1 reactivity (16). More recently, 
it has been shown that Th17 cell activation also occurs in fungal infections and Th17 cell pathway plays an important regulatory 
function in promoting protective immunoresponses, particularly in mucocutaenous candidiasis (6, 17, 18). 
 
Moreover, the immune system must tolerate colonization with commensal fungi (the mycobiome) but defends against 
fungal invasion; when this balance is disrupted (for example by immunosupression) life-threatening fungal infections develop 
(19). Moreover, in addition to the host status, the pathogenicity of the fungus also depends on a set of virulence factors (adhesins, 
hydrolytic enzymes and morphological transition from yeast to hyphal form) whose expression is often environmentally 
regulated (20). Commensal C. albicans cells exhibit the yeast morphology, whereas the yeast to hyphal transition occurs when 
fungus invades target organs, and the immune system can distinguish these fungal forms through distinct PRRs, promoting 
different Th lineage development (8, 18, 21).  
 
Here we review the role of IFN-γ in the host protection against invasive candidiasis and focus on recent progress on 
host-pathogen interactions at the molecular level leading to the production of IFN-γ by host cells.  
 
3. INTERFERON-GAMMA 
 
Immune, type II interferon, or interferon-gamma (IFN-γ), is a pleiotropic cytokine secreted by CD4 Th1, CD8, γδ T, 
and natural killer (NK) cells. Although originally defined as an agent with direct antiviral activity (22), the properties of IFN-γ 
include regulation of the immune system and the control of infectious disease. This cytokine plays an essential role in both the 
innate and adaptive phases of an immune response (23, 24). 
 
Human as well as mouse IFN-γ is encoded by a single-copy gene, generating a single 1.2.-kb mRNA-species and a 
polypeptide of 166 residues containing a cleaved hydrophobic signal sequence of 23 residues. Biologically active IFN-γ is in the 
form of a noncovalent 34-kDa homodimer. IFN-γ exerts its effects by binding to the IFN-γ receptor, composed of the IFN-γ R1 
and R2 chains, present on many lymphoid and nonlymphoid cell types (23). IFN-γ R complex utilizes the JAK/STAT signal 
pathway, specifically the receptor-associated Janus-family protein kinases Jak1 and Jak2. Upon ligand binding these kinases are 
activated, causing the phosphorylation, dimerization, and nuclear translocation of the Stat1 transcription factor (25). The signal 
transduction pathway stemming from IFN-γ is well established, but the manner in which IFN-γ-induced genes mediate this 
cytokine’s pleotropic functions remains unclear. Over 200 genes are known to be regulated by IFN-γ and several IFN-γ-regulated 
genes are themselves components of transcription factors. Additionally, IFN-γ exerts its effect on a wide variety of cell types 
owing to the broad expression pattern of the IFN-γR complex. Thus, determination of the cell types and gene products mediating 
IFN-γ’s in vivo effects remains difficult.  
 
Il is well established that one essential role of IFN-γ is to activate a number of phagocytic cell functions, including 
induction of superoxide formation, upregulation of surface molecule display (e.g. major histocompatibility complex (MHC) class 
II, FcγR, integrins), reduction of phagocytic vacuole pH, degradation of intracellular tryptophan, and enhanced killing of 
intracellular parasites (23). Mice deficient in either IFN-γ, or IFN-γ R1, or IFN-γ R2, or the signalling molecule Stat1 have 
severely impaired immune responses in vivo, as demonstrated by their increased susceptibility to microbial pathogens and certain 
viruses (26). Besides, humans with mutations in components of the IFN-γ receptor-signalling pathway have been identified. Such 
individuals have profound immunodeficiencies, particularly to intracellular microbial infections, with some individuals dying in 
early childhood as a consequence of mycobacterial infections (26).  
 
4. INTERFERON-GAMMA IN Candida albicans INFECTIONS 
 
4.1. IFN-γ is essential for host defense against invasive candidiasis 
The important role of IFN-γ in the resistance against invasive candidiasis has been clearly demonstrated several years 
ago. Knockout mice deficient in either IFN-γ or IFN-γ receptor were more susceptible than wild-type mice to invasive C. 
albicans infection (27-29). These reports demonstrated (i) that IFN-γ is required for development of protective Th1-dependent 
immunity (27, 28), (ii) that IFN-γ knockout mice produce C. albicans specific immunoglobulins in lower titers than control mice, 
and (iii) that peritoneal macrophages from these mice have an impaired nitric oxide production (29). The administration of IFN-γ 
to mice infected with C. albicans showed a beneficial effect on the outcome of the infection (30), whereas the injection of a 
monoclonal antibody to IFN-γ resulted in the development of a nonprotective Th2 rather than a protective Th1 response (31). 
Recent experiments show that concanavalin-A injected to mice allows the survival after a lethal dose of C. albicans, probably by 
promoting Th1 and Th17 responses and therefore IFN-γ and IL-17 production (32). 
 
Several mechanisms have been shown to mediate the protective effect of IFN-γ against C. albicans infections. Early in 
vitro studies demonstrated stimulatory effects of IFN-γ on the phagocytosis and killing of C. albicans by neutrophils and 
macrophages (33, 34). Exposure of adult macrophages to IFN-γ resulted in increased phagocytosis and killing of C. albicans 
(34); however, no enhancement with cord macrophages could be detected under the same experimental conditions (35). These 
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data suggested that neonatal macrophages have a normal capacity to ingest and kill Candida but cannot be fully activated by IFN-
γ, a finding that could not be attributed to lower expression or binding of IFN-γ receptor to its ligand on neonatal cells. 
Remarkably, a significantly decreased Stat-1 phosphorylation was detected in neonatal cells in response to IFN-γ, suggesting the 
possible existence of a negative regulation of IFN-γ receptor signaling in newborns (35).  
 
More recently, mutations in the STAT1 gene have been related to chronic mucocutaneous candidiasis, a chronic disease 
characterized by persistent symptomatic infection of the nails, skin and mucosa mostly by C. albicans. These mutations lead to 
defective Th1 and Th17 responses characterized by reduced production of IFN-γ, IL-17 and IL-32, which may explain the higher 
susceptibility to fungal infections, although the IFN-γ receptor pathway was intact in these patients (36). 
 
Oral mucosa is the first line of defense by acting as a physical barrier against C. albicans. In an experimental model of 
oral infection, C. albicans significantly decreased E-cadherin mRNA expression and protein production (37). E-cadherin is a 
structural protein that maintains a continous epithelial cell attachment, and supports the structural barrier against injurious agents 
passing through the oral cavity. By decreasing its expression levels, C. albicans facilitates invasion. In this experimental model, 
IFN-γ did specifically prevent the effect of C. albicans on E-cadherin gene expression, suggesting a E-cadherin-mediated IFN-γ 
role in anti-candidal defense mechanisms at the epithelial level (37). 
 
 Interestingly, C. albicans cells did not activate NADPH oxidase in dendritic cells (DCs) and were poorly killed by 
these cells; however, the C. albicans killing activity increased upon treatment of DCs with IFN-γ, indicating that IFN- γ probably 
modulates NADPH oxidase activity, the enzyme responsible for ROS production (38).  
 
Furthermore, the IFN-γ induced by the fungus during experimental candidiasis acts on the metabolic pathway involved 
in tryptophan catabolism by mediating the activation of the indoleamine 2,3-dioxygenase  enzyme (IDO) in neutrophils and 
dendritic cells at the sites of infection. IDO activation in neutrophils leads to the activation of the killing machinery while sparing 
the inflammatory response, whereas in dendritic cells results in tipping the balance between IL-12 and IL-10 production leading 
to Th1 and Treg-mediated protective immunity. IDO blockade by an enzyme inhibitor exacerbates the infection process as well 
as the associated inflammatory pathology, and in addition, abolishes resistance to reinfection caused by deregulated innate and 
adaptive immune responses. Therefore, IDO activation represents one of the mechanisms by which IFN-γ exerts a fine control on 
the inflammatory and adaptive antifungal responses (6, 39, 40).  
 
The development of vaccines against C. albicans have shown that protective adaptive immunity against fungal 
infections is mediated by Th1-Th17 cells, through an increase in IFN-γ and IL-17, both in laboratory experiments and in clinical 
trials (41-44). Therefore, it has been suggested that different preparations/extracts should be analyzed in order to choose those 
that induce greater levels of IFN-γ for the development of new vaccines (45). 
 
4.2. IFN-γ production by NK cells 
A crucial step in the control of intracellular pathogens is the early production of IFN-γ by NK cells. NK cells are an 
essential component of the innate immune response and are recruited to the site of infection within minutes following pathogen 
invasion. At the site of infection, and as a consequence of interacting with various microbial products, macrophages and dendritic 
cells produce proinflammatory cytokines (TNF-α, IL-12, IL-15 and IL-18), which bind to their receptors on NK cells, leading to 
their activation and to the rapid production and secretion of IFN-γ. This IFN-γ produced by NK cells not only serves as a first line 
of defense against invading pathogens, but may also contribute to the induction of the appropriate adaptive immune response. 
Moreover, the expression of TLRs on NK cells has been reported and several data indicate that NK cells can directly recognize 
and respond to pathogen components through TLRs by secreting IFN-γ (46-51). However, controversies remain regarding the 
TLR expression in NK cells and their responsiveness to agonists, particularly the requirement for the presence of accessory cells, 
such as dendritic cells, or accessory cytokines to respond to TLR agonists (52).  
 
Interaction of lymphokine activated killer (LAK) cells with C. albicans does not inhibit or kill the fungal pathogen by 
means of the LAK lytic machinery, but through secretion of cytokines which have stimulatory effects on phagocytic cells (53). 
Therefore, the antifungal immunity mediated by NK cells appears to occur by secretion of cytokines that activate phagocytic 
cells, although whether NK cells are stimulated directly by the fungus or indirectly in response to signals generated by activated 
bystander host cells was not clearly established (53-55). Recent studies have shown that cytokine-primed human NK cells are 
activated by direct contact with C. albicans following actin-dependent engulfment of fungal cells; this NK cell activation results 
in degranulation and the release of granulocyte-macrophage colony stimulating factor, IFN-γ and TNF-α, and induces fungal 
damage (56). It should be noted that NK cells are unable to inhibit filamentation of engulfed C. albicans, and that antifungal 
activity of NK cells is mainly attributed to secreted perforin (56).  
 
Interestingly, when the role of TLRs in triggering IFN-γ secretion by NK cells in response to yeasts and hyphae of C. 
albicans was studied, it was unexpectedly found that fungal cells cause an inhibition of IFN-γ secretion by murine NK cells. 
Killed yeasts and hyphae of C. albicans inhibited IFN-γ secretion by highly purified murine NK cells in response to TLR4 and 
TLR2 ligands, LPS and zymosan, respectively, and this effect was also observed in the presence of NK activating cytokines (IL-
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2, IL-12 and IL-15) (57). Since the role of NK cells in resistance to C. albicans appears to be basically mediated by cytokine 
production (including IFN-γ) that activates phagocytic cells (34, 53), its inhibition by C. albicans may favor the survival of the 
pathogen. Besides, this inhibitory effect may also: (i) inhibit IFN-γ production by NK cells in response to cytokines secreted by 
activated bystander cells (48), and (ii) disturb the crosstalk between NK and dendritic cells, as the IFN-γ secreted by NK cells 
controls dendritic cell maturation and their T cell stimulatory activity (58, 59). This finding suggests a mechanism of immune 
evasion, based on inhibition of NK cells, which may contribute to the virulence of C. albicans.  
 
4.3. IFN-γ production by Th1 cells 
The inflammatory environment established by the innate response influences the adaptive immune response: activation, 
expansion, and selection of pathogen-specific lymphocytes. Besides cell-cell contacts that provide activation signals via peptide-
MHC class II/TCR and classical costimulatory interactions (B7/CD28), antigen presenting cells (APCs) communicate with T 
cells via cytokine production, which is responsible for the expansion and differentiation of naïve T cells to generate mature 
phenotype, such as Th1 and Th2 cells. Th1 cells secrete IFN-γ, IL-2, TNF-α and TNF-β, whereas Th2 cells secrete IL-4, IL-5, IL-
6, IL-10, and IL-13, and down-regulate Th1 responses. IL-12 is the signature cytokine produced by cells of the innate immune 
system that influences adaptive cell immunity. IL-12 plays a central role in promoting the differentiation of naïve CD4+ T cells 
into mature Th1 effector cells and it is a potent stimulus for NK cells and CD8+ T cells to produce IFN-γ. 
 
It is well established that Th1, and not Th2, response confers protection against candidiasis. The activation of Th1 cells 
is instrumental (i) in the optimal activation of phagocytes at the sites of infection through the production of IFN-γ and (ii) in the 
help for the generation of opsonizing antibodies (6, 40). Th1 cells can exert cross-reactivity among different fungal species, as C. 
albicans and Aspergillus fumigatus, due to the conserved antigen molecules shared by fungi (60).  
 
While the Th1 cytokines IFN-γ and TNF-α are required for the successful control of the infection (6, 8, 61), Th2 
cytokines (IL-4 and IL-10) inhibit Th1 development and deactivate phagocytic effector cells. Th1 and Th2 cells derive from 
common T precursor cells, and they differentiate by the activity of several transcription factors. The transcription factor GATA-3 
is recognized as a master regulator for Th2 differentiation and it is likely that GATA-3 is a critical host factor in the 
determination of susceptibility to systemic Candida infection. Haraguchi et al. (62) demonstrated that overexpression of GATA-3 
modulates macrophage antifungal activity and enhances the susceptibility to systemic Candida infection, possibly by reducing 
the production of IFN-γ.  
 
The Linker for Activation of B cells/Non-T cell Activating Linker (LAB/NTAL) encoded by Lat2, is a known regulator 
of ITAM-coupled receptors and TLR-associated cytokine responses (63). Recently, it has been reported that LAB is involved in 
anti-fungal immunity as Lat2-/- mice are more susceptible to C. albicans infection than wild type mice. Lat2 gene is expressed by 
dendritic cells and is involved in developing a Th1 response to C. albicans, as Lat2-/- dendritic cells showed a reduced Th1 
polarization in vitro and Lat2-/- mice have a reduced production of IFN-γ (64). 
 
Romani et al. (65, 66) developed a murine model of systemic candidiasis in which resistance to reinfection with 
virulent wild-type yeasts is induced by prior exposure of mice to a low-virulence agerminative strain of C. albicans. In this 
experimental model, the development of a protective anticandidal response correlated with the detection of Th1-associated 
immunity (66, 67). Using this model in MyD88-/- mice (which are defective in the adaptor molecule MyD88, which is essential 
for signal transduction through TLRs except TLR3) (12), it was shown a default of production of Th1 cytokines (IFN-γ, IL-12, 
TNF-α) in these mice, which correlated with a diminished frequency of IFN-γ producing CD4+ T lymphocytes and an increased 
susceptibility to infection (68). These results indicate that TLR/MyD88-dependent inflammatory pathway is essential for the 
development of a protective Th1 response against C. albicans. These observations agree with those reported by Bellocchio et al. 
(69) showing that MyD88-dependent signalling is crucial for antifungal responses. Since TLR2 and TLR4 have been implicated 
in anti-Candida responses (7, 10, 69, 70), similar studies were performed in TLR2-/- and TLR4-/- mice (7, 8). IL-12 could not be 
detected in TLR2-/- mice as opposed to wild type mice, and the IFN-γ production was significantly lower in TLR2-/- mice than in 
control mice in response to both C. albicans yeasts and hyphae (71). Moreover, TLR2-/- mice showed a lower frequency of Th1 
cells than control mice (unpublished results). By contrast, TLR4-/- and C3H/HeJ mice (carrying a mutant TLR4 allele which 
confers defective TLR4-mediated signalling) showed an IL-12 and IFN-γ production similar to their respective control mice and 
accordingly, a similar frequency of IFN-γ producing CD4+ T lymphocytes (72). Therefore, these results indicate that TLR2 is the 
most important TLR involved in the interaction with C. albicans leading to a Th1 protective response, whereas TLR4 appears to 
be dispensable (7, 8, 72). However, some discrepancies about the recognition of C. albicans by TLR2 and TLR4 and its 
consequences in host protection against infection have been reported; this is probably due to different experimental approaches 
and/or the use of different yeast strains, as recognition by TLR4 appears to be strain dependent (7, 8, 69, 70, 73, 74).  
 
One important advantage of C. albicans hyphae appears to be the ability to polarize the adaptative immunity towards a 
nonprotective Th2 response. Although the mechanism for this effect is not completely understood, some relevant information has 
been achieved. The most important difference in the secretory response to both fungal morphotypes is the well-documented 
higher production of IL-12 in response to yeasts, which is accompanied by a Th1 type response. IL-12 production by human 
blood monocytes, as well as mouse and human dendritic cells, basically occurs in response to the yeast form, whereas a reduced 
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IL-12 production is elicited upon exposure to hyphae (75-78). Romani and co-workers observed that dendritic cells pulsed in 
vitro with yeast and transferred back into mice, stimulated Th1 immune responses, while dendritic cells exposed to fungal 
filaments induced Th2 responses (76, 78, 79). On the other hand, it has been demonstrated that dectin-1, a phagocytic receptor for 
β-glucan, either alone or in collaboration with TLR2, elicits a strong inflammatory response (enhanced stimulation of TNF-α and 
IL-12) to yeasts (80, 81). It has been shown that dectin-1 mediates in vitro macrophage recognition of C. albicans yeasts but not 
hyphae, since hyphal cells do not appear to expose the β-glucan at the cell surface, suggesting that failure of hyphae to activate 
dectin-1 might contribute to an impaired Th1 response (82, 83). However, exposure of β-glucan in yeasts or hyphae surfaces 
appears to be similar during in vivo infection (84). 
 
The Th1-versus Th2 dichotomy has dominated T cell biology for many years. However, another T helper subset, the 
Th17 lineage that secretes IL-17, has risen to prominence (17, 18, 85, 86). Th17 cell development occurs in the presence of TGF-
β and IL-6 and is opposed by Th1 cytokines. Th17 cells are maintained in the presence of the IL-12-related cytokine IL-23. IL-17 
induces chemokine production at the sites of infection and causes recruitment of neutrophils. IL-17 receptor-deficient mice are 
more susceptible than control mice to systemic candidiasis and this effect may be attributed to a decreased influx of neutrophils 
to infected organs (85). It has been described that the Th17 pathway do develop in response to C. albicans (87, 88). Although one 
report suggested that the Th17 pathway acts as negative regulator of the Th1 mediated immune resistance to C. albicans (89), 
most data are consistent with a protective role of IL-17 in systemic candidemia (85, 90) and, in addition, it has been shown that 
C. albicans-specific Th17 cells produced IFN-γ and IL-17 but no IL-10, in a IL-1β mediated manner (42). Furthermore, 
immunization with a recombinant vaccine causes a Th1, Th17, and Th1/17 mediated protective immunity against C. albicans 
infection in mice, and this response involves CD4+ T-cell-derived IFN-γ and IL-17, as well as functional phagocytic effectors 
(41). 
  
4.4. IFN-γ production by γδ T cells, NKT cells and CD8 T cells   
A minority of T cells expresses a TCR consisting of γ and δ chains, and those cells are primarily CD4+. These chains 
are encoded by few genes and accordingly, the γδ repertoire is very limited. Despite sharing many similarities with αβ T cells, 
their method of activation differs markedly as the recognition of antigen by γδ T cells may be not MHC-restricted. There are two 
main population subsets of γδ T cells: γδ2 T cells comprise a very small percentage of circulating lymphocytes, and γδ1 T cells 
are resident in the mucosal-associated lymphoid tissue (91, 92). Although the function of γδ T cells appears to be dependent on 
several factors, including tissue distribution, local microenvironment, and stage of the immune response, one attribute of these 
cells is the production of IFN-γ upon activation. It was early shown that the γδ T cells enhance macrophage nitric oxide 
production and anti-Candida activity in vitro (93). γδ T cells may contribute to immunosurveillance at the body surface, as mice 
deficient in γδ T cells or depleted in these cells are highly susceptible to orogastric candidiasis (94). γδ1 T circulating population 
can proliferate and produce IFN-γ and IL-17 in response to C. albicans in vitro, and therefore may play an important role in the 
defense against infection (92, 95).  
 
NKT cells constitute a subset of mature T lymphocytes characterized by the coexpression of αβ TCR as well as the 
NK1.1. cell marker. These cells recognize lipids in the context of the nonclassical MHC molecule CD1, and are able to rapidly 
release vast quantities of diverse effector cytokines, including IFN-γ. NKT cells play a role in immunity against fungal infections, 
including candidiasis, probably by IFN-γ production and polarization towards Th1 response (96-98). It has been recently reported 
that coinfection with commensal bacteria, or treatment with bacterial glicolipids, exacerbates systemic C. albicans infection 
through IFN-γ produced in part by NKT cells; the increased levels of IFN-γ in the early phase of infection caused a dramatic 
decrease in the blood and bone marrow neutrophils, suggesting the hypothesis that the timing and quantity of IFN-γ determine the 
effect on neutrophils and other bone marrow cells, and therefore may modulate the fate of fungal infection (99).  
 
CD8+ T cells play a pivotal role in immune responses against many viruses and tumors, and may also contribute to 
immunity to fungi (4, 100). These T cells recognize antigens that are presented on the surface of host cells by MHC class I 
molecules, leading to their destruction, and therefore are also known as cytotoxic T cells. The possible role of CD8+ T cells in 
resistance to candidiasis has been somewhat controversial, although some early reports suggested a role of these cells during 
infection (100, 101). It is accepted that both CD4+ and CD8+ T cells are necessary for elimination of some fungal pathogens; in 
the primary stages of many fungal diseases the presence of CD4+ T cells is essential for host survival, whereas CD8+ T cells are 
only necessary to restrict infection (100, 102). The main effector mechanisms of CD8+ T cells are cytotoxicity and cytokine 
secretion (IFN-γ). The role of cytotoxicity in host defense against fungi is not well delineated, whereas the activity of cytokines is 
better understood. The Th1 cytokine IL-12 is also a potent stimulus for CD8+ T cells to produce IFN-γ. The frequency of IFN-γ 
producing CD8+ T lymphocytes is diminished in MyD88-deficient mice as compared with wild-type mice, in agreement with the 
default of production of Th1 cytokines (IFN-γ, IL-12, TNF-α) detected in these mice, as well as with their strong susceptibility to 
candidiasis (8, 68). 
  
As a conclusion, CD8, NKT and γδ T cells may have a role in protection against candidiasis. Probably the major role of 
these cells is the cytokine production, which is instrumental in mobilizing and activating antifungal effectors, thus providing 
prompt and effective control of infectivity once the fungus has been established itself in mucosal tissues or spread to internal 
organs.  
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5. PERSPECTIVE 
 
The level of our understanding of fungal-host interactions has clearly progressed in the last few years. Although the 
important role of IFN-γ secreting Th1 responses in protection against C. albicans infections has been well established several 
years ago, recently there has raised increasing interest in how adaptive immune responses are controlled by the innate immune 
system. Researchers have focused on the discovery of PRRs that, upon recognition of MAMPs on fungal cells, initiate adaptive 
responses through activation and maturation of dendritic cells. Considerably new information has been gained in this field 
concerning the role of TLRs, dectin-1, galectin-3 and dectin-2, as well as cooperation between dectin-1 and TLR2, although we 
are far to completely discerning the intricate molecular mechanisms leading to the elicitation of a protective immune response to 
C. albicans infections.  
 
The discovery of IL-23/Th17 pathway in response to C. albicans has represented a significant advance in the field of 
adaptive immune response. Modulation of this inflammatory Th17 response is a potential target for development of new 
strategies to stimulate protective immunity to C. albicans. Two types of human Th17 cells with distinct effector function and 
differentiation requirements have been described; C. albicans-specific Th17 cells produced IFN-γ and IL-17 but no IL-10, in a 
IL-1β mediated manner. Therefore, strategies to generate this subpopulation can be of potential interest for anti C. albicans 
immunotherapies (42). It has been shown that immunization with a recombinant vaccine primed Th1, Th17 and Th1/17 
lymphocytes, which produced proinflammatory cytokines that enhanced phagocytic killing of Candida (41). 
 
The ultimate objective is to apply our knowledge of how C. albicans stimulates the immune response to improve the 
therapy of candidiasis and thus the clinical control of fungal infections in the at-risk population. There are several strategies for 
immunotherapy related to IFN-γ; one of them is the use of recombinant (r) IFN-γ as adjunctive therapeutic. Despite the 
widespread use of prophylactic rIFN-γ in chronic granulomatous disease (a genetic disorder characterized by recurrent bacterial 
and fungal infections and tissue granuloma formation), invasive fungal infection has remained a persistent problem in these 
patients (103). However, on the basis of a large volume of other preclinical studies and phase I and II clinical trials (104), 
adjunctive rIFN-γ (in combination with antifungal agents) have been further evaluated, with no relevant advances. Alternatively, 
the generation of functionally active anti-C. albicans IFN-γ secreting T cells is feasible, and this was suggested as a potential 
treatment option for patients with candidiasis after alogenic haematopoietic stem-cell transplant (105). 
 
Vaccination strategies against C. albicans components that bias the immune responses towards Th1/17 may represent 
an effective immunotherapeutic tool (106). For instance, vaccination with recombinant Als3p N-terminal portion protects mice 
from both systemic and mucosal infections by stimulating peripheral blood mononuclear cell production of both IFN-γ and IL-
17A. This vaccine has been recently tested in a phase I clinical trial with promising results, as it was found to be safe, well 
tolerated and induced strong humoral and cellular immune responses, with increased IL-17 and IFN-γ production (43, 44). Also, 
new synthetically prepared glycooligosaccharides conjugates mimicking Candida cell wall antigens have been assessed in vivo 
and in vitro to test their immunobiological efficacy. The conjugates biased the immune responses towards Th1 and Th17, and 
represent prospective immunobiological components for further immunopharmacologically relevant Candida vaccine design 
(107). 
 
Finally, it should be noted that recent findings have demonstrated a significant role of type I IFN in host defense against 
C. albicans. Smeekens et al. (108) have shown that type I IFN has a crucial role in anti-Candida host defense in humans and that 
type I IFN induced by Candida modulates Th1/Th17 cytokine profiles, with an increase in IFN-γ and a decrease in IL-17. Other 
reports have shown that conventional DCs are able to mount a type I IFN response against C. albicans (109) and that IFN-β 
production by DCs is crucial for immunity to C. albicans (110). Although the precise effect of type I IFNs on anti Candida host 
defense is still being debated, mechanisms inducing type I IFN production may also represent a target for immunointervention 
against C. albicans.  
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